Home
All Companies
Companies in F
F. Hoffmann-La Roche Ltd.
Infectious Immunology Reagents, Instruments and Test Kits

General Medicine & Spec

Summary

Table of Contents

Infectious Immunology Reagents, Instruments and Test Kits

Publication date: June 2012
Report size: 105 pages

Keywords : Immunology, Infectious Disease

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

The report provides industry landscape, competitive landscape and industry trends data on the infectious immunology industry . The report provides comprehensive data on the major industry developments affecting the industry, and key analytical content on the industry dynamics. The report also reviews the competitive landscape and technology offerings.

Scope of the Research

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Key sectors covered include hepatitis viruses, retroviruses, bacteriology and other viruses.
- Annualized industry revenues data from 2003 to 2010, projection forward for 7 years to 2017. Firms shares data for 2009.
- Qualitative analysis of key industry trends, industry drivers, and restraints by each category within infectious immunology industry .
- The report also covers data on the leading industry players, the competitive landscape, and the leading new product development and technologies.
- Key Companies covered include F. Hoffmann-La Roche Ltd, Qiagen N.V., Becton, Dickinson and Firms, Gen-Probe Incorporated and Beckman Coulter.

Why Should You Get This Report?

- Develop business strategies by understanding the trends and developments that are driving the infectious immunology industry globally.
- Design and develop your product development, industry ing and sales strategies.
- Develop successful market-entry strategies .
- Identify key players best positioned to take advantage of the emerging industry opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What’s the next big thing in the infectious immunology industry landscape? – Identify, understand and decide.
- Make more informed business decisions from the insightful and in-depth analysis of the global infectious immunology industry and the factors shaping it.

Global General Medicine And Specialty Medicine Industry

1 Table of contents

I Table of contents 3
I. 1 List of Data tables 5
I. 2 List of Charts 6

II Introduction and Overview 7
II. 1 Introduction 7
II. 2 GlobalData Report Guidance 7

III Infectious Immunology Overview 8
4 World Infectious Immunology: March ket Characterization 9
IV. 1 Infectious Immunology March ket, Global, Sales (USD Million), Historical data, 2003?2010 9
IV. 2 Infectious Immunology March ket, Global, Sales (USD Million), Forecasted data, 2010?2017 10
IV. 3 Infectious Immunology, Key March ket Trends 11
IV. 3.1 Demand for Rapid Methods for the Molecular Diagnosis of the Infectious Diseases is Altering the Infectious Immunology Landscape 11
IV. 3.2 Microfluidic Systems for Pathogen Testing are Expected to find Increased Adoption in the Future 12
IV. 3.3 Point of Care Testing Technology is the Current Trend in the Infectious Immunology March ket 12
IV. 3.4 Technological Advancements such as Nanotechnology and PNA Florescence in Situ Hybridization (FISH) is the Latest Technological Trend for Early Detection 13
IV. 3.5 Shift Towards Automation and Consolidation of Laboratories Expects to Gain Popularity amongst the Laboratories and IVD Manufacturers 13
IV. 4 Infectious Immunology, March ket Dynamics 15
IV. 4.1 March ket Drivers 15
IV. 4.2 March ket Restraints 19
5 World Infectious Immunology March ket: Analysis By Segment 21
V. 1 Hepatitis Viruses: March ket Characterization 21
V. 1.1 Hepatitis Viruses March ket, Global, Sales (USD Million), Historical data, 2003?2010 21
V. 1.2 Hepatitis Viruses March ket, Global, Sales (USD Million), Forecasted data 2010?2017 22
V. 1.3 Hepatitis Viruses, March ket Drivers 23
V. 1.4 Hepatitis Viruses, March ket Restraint: Social Factors Associated with Hepatitis Might Act as Deterrent 23
V. 2 Retroviruses: March ket Charaterization 24
V. 2.1 Retroviruses March ket, Global, Sales (USD Million), Historical data, 2003?2010 24
V. 2.2 Retroviruses March ket, Global, Sales (USD Million), Forecasted data, 2010?2017 25
V. 2.3 Retroviruses, March ket Drivers: Increasing Prevalence of HIV Infection to Drive the Retroviruses March ket 26
V. 2.4 Retroviruses Devices, March ket Restraint: Lack of Awareness of HIV Infection is a Barrier for March ket Growth 26
V. 3 Bacteriology: March ket Charaterization 27
V. 3.1 Bacteriology March ket, Global, Sales (USD Million), Historical data, 2003?2010 27
V. 3.2 Bacteriology March ket, Global, Sales (USD Million), Forecasted data, 2010?2017 28
V. 3.3 Bacteriology, March ket Driver: Emergence of Drug Resistant Infectious Strains is Expected to Lead to Higher Demand for Diagnostic Tests 29
V. 3.4 Bacteriology, March ket Restraint: Easy Replication of Consumables in Developing Economies Put Pricing Pressure on Multinational Players 29
V. 4 Other Virology: March ket Charaterization 30
V. 4.1 Other Virology, Global, Sales (USD Million), Historical data, 2003?2010 30
V. 4.2 Other Virology, Global, Sales (USD Million), Forecasted data, 2010?2017 31
V. 4.3 Other Virology, March ket Drivers 32
V. 4.4 Others Virology, March ket Restraint: Shortage of Skilled Professionals is a Major Concern for Laboratories Handling Emerging Viral Infections 32

VI Infectious Immunology March ket, by Country, Sales (USD Million), 2002–2016 33
VI. 1 World Infectious Immunology March ket, Sales by Country, 2002?2016 33
VI. 1.1 Infectious Immunology March ket, US, Sales (USD Million), Historical data, 2003?2010 33
VI. 1.2 Infectious Immunology March ket, US, Sales (USD Million), Forecasted data, 2010?2017 35
VI. 1.3 Infectious Immunology March ket, Canada, Sales (USD Million), Historical data, 2003?2010 36
VI. 1.4 Infectious Immunology March ket, Canada, Sales (USD Million), Forecasted data, 2010?2017 37
VI. 1.5 BInfectious Immunology March ket, UK, Sales (USD Million), Historical data, 2003?2010 38
VI. 1.6 Infectious Immunology March ket, UK, Sales (USD Million), Forecasted data, 2010?2017 39
VI. 1.7 Infectious Immunology March ket, Germany, Sales (USD Million), Historical data, 2003?2010 41
VI. 1.8 Infectious Immunology March ket, Germany, Sales (USD Million), Forecasted data, 2010?2017 42
VI. 1.9 Infectious Immunology March ket, France, Sales (USD Million), Historical data, 2003?2010 43
VI. 1.10 Infectious Immunology March ket, France, Sales (USD Million), Forecasted data, 2010?2017 44
VI. 1.11 Infectious Immunology March ket, Italy, Sales (USD Million), Historical data, 2003?2010 45
VI. 1.12 Infectious Immunology March ket, Italy, Sales (USD Million), Forecasted data, 2010?2017 46
VI. 1.13 Infectious Immunology March ket, Spain, Sales (USD Million), Historical data, 2003?2010 47
VI. 1.14 Infectious Immunology March ket, Spain, Sales (USD Million), Forecasted data, 2010?2017 48
VI. 1.15 Infectious Immunology March ket, Japan, Sales (USD Million), Historical data, 2003?2010 49
VI. 1.16 Infectious Immunology March ket, Japan, Sales (USD Million), Forecasted data, 2010?2017 50
VI. 1.17 Infectious Immunology March ket, China, Sales (USD Million), Historical data, 2003?2010 51
VI. 1.18 Infectious Immunology March ket, China, Sales (USD Million), Forecasted data, 2010?2017 52
VI. 1.19 Infectious Immunology March ket, India, Sales (USD Million), Historical data, 2003?2010 53
VI. 1.20 Infectious Immunology March ket, India, Sales (USD Million), Forecasted data, 2010?2017 54
VI. 1.21 Infectious Immunology March ket, Australia, Sales (USD Million), Historical data, 2003?2010 55
VI. 1.22 BInfectious Immunology March ket, Australia, Sales (USD Million), Forecasted data, 2010?2017 56
VI. 1.23 Infectious Immunology March ket, Brazil, Sales (USD Million), Historical data, 2003?2010 57
VI. 1.24 Infectious Immunology March ket, Brazil, Sales (USD Million), Forecasted data, 2010?2017 58
7 World Infectious Immunology March ket: Competitive Assessment 59
VII. 1 Infectious Immunology March ket, Global, Key Market Shares s (%), 2009 59
VII. 2 Infectious Immunology March ket, Key March ket Participants 60
VII. 2.1 F. Hoffmann-La Roche Ltd 60
VII. 2.2 Qiagen N.V. 64
VII. 2.3 Becton, Dickinson and Firms 67
VII. 2.4 Gen-Probe Incorporated 70
VII. 2.5 Beckman Coulter 73
VII. 3 Key Infectious Immunology Devices in the March ket 75
VII. 3.1 COBAS AmpliPrep/COBAS TaqMan HBV Test, Roche Diagnostics 75
VII. 3.2 COBAS AMPLICOR Chlamydia Trachomatis/Neisseria Gonorrhoeae (CT/NG) Test, Roche Diagnostics 75
VII. 3.3 digene HC2 CT/GC DNA Test, Qiazen NV 75
VII. 3.4 QIAamp Viral RNA, Qiazen NV 76
VII. 3.5 BD Max System, Becton, Dickinson and Firms 76
VII. 3.6 APTIMA COMBO 2 Assay, Gen-Probe 76
VII. 3.7 ProFlu+ Assay, Gen-Probe 76

VIII Infectious Immunology, Pipeline Assessment 77
VIII. 1 Infectious Immunology, Pipeline Products, by Sector 77
VIII. 2 List of Promising Infectious Immunology Products under Clinical Development 78
VIII. 3 Profiles of Promising Infectious Immunology Products under Clinical Development 80
VIII. 3.1 Seeplex FluA ACE Subtyping Test 80
VIII. 3.2 Anyplex CT/NG Real-time Detection Assay 80
VIII. 3.3 Seeplex MRSA ACE Detection Assay 81
VIII. 3.4 APTIMA HPV Assay 81
VIII. 3.5 ARCHITECT i4000SR Anti-HAV IgG Assay 83
VIII. 3.6 Neo-Natal HIV Test 83
VIII. 3.7 Multiplo Rapid HBV/HIV/HCV Antibody Test 84
VIII. 3.8 DPP HIV 1/2 Screening Assay 84
VIII. 3.9 Diagnostic Test-Cytomegalovirus 86
VIII. 3.10 Artus CMV Assay 86
VIII. 3.11 TessArray RM-Flu Test 88
VIII. 3.12 LightCycler September tiFast Test MGRADE 89
9 World Infectious Immunology March ket – Merger and Acquisition Landscape 91
IX. 1 World Infectious Immunology March ket – Deals Overview 91
IX. 2 Key Acquisitions in Infectious Immunology March ket 93
IX. 2.1 Danaher to Acquire Beckman Coulter, Inc. for US$ 83.50 per share or US$ 6.8 billion 93
IX. 2.2 Thermo Fisher Scientific Completes Acquisition of Ahura Scientific 93
IX. 2.3 Fujirebio Takes Over Innogenetics from Abbott Laboratories 93
IX. 2.4 Gen-Probe Completes Acquisition of Prodesse 94
IX. 2.5 Solvay Pharmaceuticals takes over Innogenetics 94
IX. 2.6 Abbott Laboratories Takes Over Ibis Biosciences from Isis Pharmaceuticals 94

X Appendix 95
X. 1 Definitions 96
X. 1.1 Infectious Immunology 96
X. 2 Acronyms 96
X. 3 Sources 99
X. 4 Research Methodology 99
X. 5 Secondary Research 99
X. 6 Primary Research 100
X. 7 Models 100
X. 8 Forecasted data s 100
X. 9 Expert Panels 101
X. 10 GlobalData Consulting 101
X. 11 Contact Us 101
X. 12 Disclaimer 101

1.1 List of Data tables
Data table 1: Infectious Immunology March ket, Global, Sales (USD Million), 2003?2010 9
Data table 2: Infectious Immunology March ket, Global, Sales (USD Million), 2010?2017 10
Data table 3: Infectious Immunology, US, Number of Completed Laboratory Acquisitions, 2002–2008 14
Data table 4: Hepatitis Viruses March ket, Sales (USD Million), 2003?2010 21
Data table 5: Hepatitis Viruses March ket, Sales (USD Million), 2010?2017 22
Data table 6: Retroviruses March ket, Global, Sales (USD Million), 2003?2010 24
Data table 7: Retroviruses March ket, Sales (USD Million), 2010?2017 25
Data table 8: Bacteriology March ket, Sales (USD Million), 2003?2010 27
Data table 9: Bacteriology March ket, Sales (USD Million), 2010?2017 28
Data table 10: Other Virology March ket, Sales (USD Million), 2003?2010 30
Data table 11: Other Virology March ket, Sales (USD Million), 2010?2017 31
Data table 12: Infectious Immunology March ket, US, Sales (USD Million), 2003?2010 33
Data table 13: Infectious Immunology March ket, US, Sales (USD Million), 2010?2017 35
Data table 14: Infectious Immunology March ket, Canada, Sales (USD Million), 2003?2010 36
Data table 15: Infectious Immunology March ket, Canada, Sales (USD Million), 2010?2017 37
Data table 16: Infectious Immunology March ket, UK, Sales (USD Million), 2003?2010 38
Data table 17: Infectious Immunology March ket, UK, Sales (USD Million), 2010?2017 39
Data table 18: Infectious Immunology March ket, Germany, Sales (USD Million), 2003?2010 41
Data table 19: Infectious Immunology March ket, Germany, Sales (USD Million), 2010?2017 42
Data table 20: Infectious Immunology March ket, France, Sales (USD Million), 2003?2010 43
Data table 21: Infectious Immunology March ket, France, Sales (USD Million), 2010?2017 44
Data table 22: Infectious Immunology March ket, Italy, Sales (USD Million), 2003?2010 45
Data table 23: Infectious Immunology March ket, Italy, Sales (USD Million), 2010?2017 46
Data table 24: Infectious Immunology March ket, Spain, Sales (USD Million), 2003?2010 47
Data table 25: Infectious Immunology March ket, Spain, Sales (USD Million), 2010?2017 48
Data table 26: Infectious Immunology March ket, Japan, Sales (USD Million), 2003?2010 49
Data table 27: Infectious Immunology March ket, Japan, Sales (USD Million), 2010?2017 50
Data table 28: Infectious Immunology March ket, China, Sales (USD Million), 2003?2010 51
Data table 29: Infectious Immunology March ket, China, Sales (USD Million), 2010?2017 52
Data table 30: Infectious Immunology March ket, India, Sales (USD Million), 2003?2010 53
Data table 31: Infectious Immunology March ket, India, Sales (USD Million), 2010?2017 54
Data table 32: Infectious Immunology March ket, Australia, Sales (USD Million), 2003?2010 55
Data table 33: Infectious Immunology March ket, Australia, Sales (USD Million), 2010?2017 56
Data table 34: Infectious Immunology March ket, Brazil, Sales (USD Million), 2003?2010 57
Data table 35: Infectious Immunology March ket, Brazil, Sales (USD Million), 2010?2017 58
Data table 36: Infectious Immunology March ket, Global, Key Market Shares s (%), 2009 59
Data table 37: F. Hoffmann-La Roche Ltd, March keted Products in Infectious Immunology March ket, 2010 61
Data table 38: F. Hoffmann-La Roche Ltd, Pipeline Products in Infectious Immunology March ket, 2010 61
Data table 39: Qiagen N.V., Key March keted Products, 2010 64
Data table 40: Qiagen N.V., Pipeline Products in Infectious Immunology March ket, 2010 64
Data table 41: Becton, Dickinson and Firms, Key March keted Products, 2010 67
Data table 42: Becton, Dickinson and Firms, Pipeline Products in Infectious Immunology March ket, 2010 67
Data table 43: Gen-Probe Incorporated, Key March keted Products, 2010 70
Data table 44: Gen-Probe Incorporated, Pipeline Products in Infectious Immunology March ket, 2010 70
Data table 45: Beckman Coulter, Key March keted Products, 2010 73
Data table 46: Beckman Coulter, Pipeline Products in Infectious Immunology March ket, 2010 73
Data table 47: List of Promising Retroviruses Products under Clinical Development, 2010 78
Data table 48: List of Promising Hepatitis Viruses Products under Clinical Development, 2010 78
Data table 49: List of Promising Bacteriology Products under Clinical Development, 2010 79
Data table 50: List of Promising Other Virology Products under Clinical Development, 2010 79
Data table 51: Seeplex FluA ACE Subtyping Test, Product Status, 2010 80
Data table 52: Anyplex CT/NG Real-time Detection Assay, Product Status, 2010 80
Data table 53: Seeplex MRSA ACE Detection Assay, 2010 81
Data table 54: APTIMA HPV Assay, Product Status, 2010 81
Data table 55: APTIMA HPV Assay - Comparison of Three High-risk HPV (HR-HPV) Testes on ASC Samples With Follow-up 82
Data table 56: APTIMA HPV Assay - Does RNA Testing Detect Clinically Significant HPV Infection 82
Data table 57: ARCHITECT i4000SR Anti-HAV IgG Assay, Product Status, 2010 83
Data table 58: Neo-Natal HIV Test, Product Status, 2010 83
Data table 59: Multiplo Rapid HBV/HIV/HCV Antibody Test, Product Status, 2010 84
Data table 60: DPP HIV 1/2 Screening Assay, Product Status, 2010 84
Data table 61: DPP HIV 1/2 Screening Assay - Study to Establish the Ability of the Chembio Diagnostics Systems, Inc. DPP HIV 1/2 Rapid Test to Qualitatively Detect the Presence of Antibodies Against HIV-1 in Oral Fluid, Whole Blood (Capillary and Venous), Serum and Plasma 85
Data table 62: Diagnostic Test-Cytomegalovirus, Product Status, 2010 86
Data table 63: Artus CMV Assay, Product Status, 2010 86
Data table 64: Artus CMV Assay - Clinical Evaluation of the Artus CMV RG PCR Test 87
Data table 65: TessArray RM-Flu Test, Product Status, 2010 88
Data table 66: LightCycler September tiFast Test MGRADE, Product Status, 2010 89
Data table 67: LightCycler September tiFast Test MGRADE - Value of the LightCycler September tiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients 89
Data table 68: Infectious Immunology March ket, Global, Mergers and Acquisitions, 2007–2010 91

1.2 List of Charts

Chart 1: Infectious Immunology, March ket Segmentation 8
Chart 2: Infectious Immunology March ket, Global, Sales (USD Million), 2003?2010 9
Chart 3: Infectious Immunology March ket, Global, Sales (USD Million), 2010?2017 10
Chart 4: Number of Completed Laboratory Acquisitions, 2002–2008 14
Chart 5: Infectious Immunology, March ket Drivers and Restraints 15
Chart 6: Hepatitis Viruses March ket, Sales (USD Million), 2003?2010 21
Chart 7: Hepatitis Viruses March ket, Sales (USD Million), 2010?2017 22
Chart 8: Retroviruses March ket, Global, Sales (USD Million), 2003?2010 24
Chart 9: Retroviruses March ket, Sales (USD Million), 2010?2017 25
Chart 10: Bacteriology March ket, Sales (USD Million), 2003?2010 27
Chart 11: Bacteriology March ket, Sales (USD Million), 2010?2017 28
Chart 12: Other Virology March ket, Sales (USD Million), 2003?2010 30
Chart 13: Other Virology March ket, Sales (USD Million), 2010?2017 31
Chart 14: Infectious Immunology March ket, US, Sales (USD Million), 2003?2010 33
Chart 15: Infectious Immunology March ket, US, Sales (USD Million), 2010?2017 35
Chart 16: Infectious Immunology March ket, Canada, Sales (USD Million), 2003?2010 36
Chart 17: Infectious Immunology March ket, Canada, Sales (USD Million), 2010?2017 37
Chart 18: Infectious Immunology March ket, UK, Sales (USD Million), 2003?2010 38
Chart 19: Infectious Immunology March ket, UK, Sales (USD Million), 2010?2017 39
Chart 20: Infectious Immunology March ket, Germany, Sales (USD Million), 2003?2010 41
Chart 21: Infectious Immunology March ket, Germany, Sales (USD Million), 2010?2017 42
Chart 22: Infectious Immunology March ket, France, Sales (USD Million), 2003?2010 43
Chart 23: Infectious Immunology March ket, France, Sales (USD Million), 2010?2017 44
Chart 24: Infectious Immunology March ket, Italy, Sales (USD Million), 2003?2010 45
Chart 25: Infectious Immunology March ket, Italy, Sales (USD Million), 2010?2017 46
Chart 26: Infectious Immunology March ket, Spain, Sales (USD Million), 2003?2010 47
Chart 27: Infectious Immunology March ket, Spain, Sales (USD Million), 2010?2017 48
Chart 28: Infectious Immunology March ket, Japan, Sales (USD Million), 2003?2010 49
Chart 29: Infectious Immunology March ket, Japan, Sales (USD Million), 2010?2017 50
Chart 30: Infectious Immunology March ket, China, Sales (USD Million), 2003?2010 51
Chart 31: Infectious Immunology March ket, China, Sales (USD Million), 2010?2017 52
Chart 32: Infectious Immunology March ket, India, Sales (USD Million), 2003?2010 53
Chart 33: Infectious Immunology March ket, India, Sales (USD Million), 2010?2017 54
Chart 34: Infectious Immunology March ket, Australia, Sales (USD Million), 2003?2010 55
Chart 35: Infectious Immunology March ket, Australia, Sales (USD Million), 2010?2017 56
Chart 36: Infectious Immunology March ket, Brazil, Sales (USD Million), 2003?2010 57
Chart 37: Infectious Immunology March ket, Brazil, Sales (USD Million), 2010?2017 58
Chart 38: Infectious Immunology March ket, Global, Key Market Shares s (%), 2009 59
Chart 39: Infectious Immunology, Strategic Competitive Assessment, 2010 60
Chart 40: F. Hoffmann-La Roche Ltd, SWOT ANALYSIS, 2010 62
Chart 41: Qiagen N.V., SWOT, 2010 65
Chart 42: Becton, Dickinson and Firms, SWOT 68
Chart 43: Gen-Probe Incorporated, SWOT, 2010 71
Chart 44: Beckman Coulter, SWOT, 2010 73
Chart 45: Infectious Immunology, Pipeline Products, by Sector, 2010 77
Chart 46: Infectious Immunology March ket, Financial Deal Analysis-Deal Volume and Value, from 2006 to 2010 91F. Hoffmann-La Roche Ltd
Qiagen N.V.
Becton, Dickinson and Firms
Gen-Probe Incorporated
Beckman Coulter

Talk to Robyn

00 1 718 213 49 04

Send Your Request

Follow

Add to circles Subscribe to our RSS feeds!

Global General Medicine And Specialty Medicine Industry : Latest Reports

Light Sciences Oncology, Inc. - Product Pipeline Review - 2013

$ 1 500
Company report
May 2013
by Global Markets Direct

Light Sciences Oncology, Inc. - Product Pipeline Review - 2013 Summary Global Market Direct's pharmaceuticals report, ?Light Sciences Oncology, Inc. - Product Pipeline Review - 2013? provides data on ...

Hadasit Medical Research Services & Development Ltd - Product Pipeline Analysis, 2013 Update

$ 750
Company report
May 2013
by Global Data

Summary Hadasit Medical Research Services & Development Ltd (Hadasit Ltd) is a biomedical technology company. It provides, promotes and commercializeS pre-clinical and clinical research and development ...

General Nutrition Centers Inc Market Analysis in Consumer Health (World)

$ 532
Company report
March 2013
by Euromonitor International

With its strong assortment of GNC-branded vitamins and dietary supplements, sports nutrition and weight management products, the industry player has enjoyed stable growth amidst global economic turmoil. ...

Ziopharm Oncology, Inc - Mergers & Acquisi ...

March 2013 $ 350

Clovis Oncology, Inc. - Mergers & Acquisit ...

March 2013 $ 350

Champions Oncology, Inc. (csbr) - Financia ...

March 2013 $ 300

Avantogen Oncology, Inc. (avto) - Strategi ...

March 2013 $ 300

Fresenius Kabi Oncology Limited (fkonco) - ...

March 2013 $ 300

Curesearch Children%s Oncology Group Swot ...

March 2013 $ 300

Dental Patient Care America Inc (dpat) - S ...

March 2013 $ 300

More Reports:

General Medicine and Specialty Medicine in Australia (11)

General Medicine and Spe... in China (19)

General Medicine and Sp... in France (11)

General Medicine and S... in Germany (11)

General Medicine and Spe... in India (12)

General Medicine and Spe... in Italy (12)

General Medicine and Spe... in Spain (11)

General Med... in the United Kingdom (12)

General Medi... in the United States (28)

Company Reports

ZIOPHARM Oncology Inc.

Luye Pharma Group Ltd.

Ramsay Health Care Ltd.

Ontario Teachers' Pension Plan

Fresenius Kabi Oncology Ltd.

Agropharm

Abraaj Capital

Mepha Pharma AG

NicOx S.A.

Forest Laboratories Inc.

Global General Medicine And Specialty Medicine Industry : Latest Downloads

Company Report: General Medicine and Specialty Medicine for Year 2013

Company report
May 2013
2 pages

Company Report: General Medicine and Specialty Medicine for Year 2013

Company report
May 2013
3 pages

... Hospital) at ghaziabad, uttar pradesh. The hospital would offer a wide range of healthcare services in various fields including cardiology, radiology, orthopaedics, trauma, pathology, physiotherapy ...

Company Report: General Medicine and Specialty Medicine for Year 2013

Company report
April 2013
3 pages

Related Market Segments :

Immunology

Infectious Disease

Company Reports

Specialty Group

Dubai Healthcare City

Country Reports

World

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.